Brain Hemorrhage - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Brain Hemorrhage - Pipeline Review, H1 2016', provides an overview of the Brain Hemorrhage pipeline landscape. The report provides comprehensive information on the therapeutics under development for Brain Hemorrhage, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Brain Hemorrhage and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Brain Hemorrhage - The report reviews pipeline therapeutics for Brain Hemorrhage by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Brain Hemorrhage therapeutics and enlists all their major and minor projects - The report assesses Brain Hemorrhage therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Brain Hemorrhage Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Brain Hemorrhage - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Brain Hemorrhage pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Brain Hemorrhage Overview 6 Therapeutics Development 7 Pipeline Products for Brain Hemorrhage - Overview 7 Brain Hemorrhage - Therapeutics under Development by Companies 8 Brain Hemorrhage - Pipeline Products Glance 9 Late Stage Products 9 Clinical Stage Products 10 Early Stage Products 11 Brain Hemorrhage - Products under Development by Companies 12 Brain Hemorrhage - Companies Involved in Therapeutics Development 13 Edge Therapeutics, Inc. 13 F. Hoffmann-La Roche Ltd. 14 Fina Biotech 15 MediPost Co., Ltd. 16 Pfizer Inc. 17 Remedy Pharmaceuticals, Inc. 18 Brain Hemorrhage - Therapeutics Assessment 19 Assessment by Monotherapy Products 19 Assessment by Target 20 Assessment by Mechanism of Action 22 Assessment by Route of Administration 24 Assessment by Molecule Type 26 Drug Profiles 28 alteplase - Drug Profile 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 aprotinin - Drug Profile 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 CN-105 - Drug Profile 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 glyburide - Drug Profile 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 PF-05230907 - Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 Pneumostem - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 PRC-14 - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 RMP-HPE - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 Stem Cell Therapy for Articular Cartilage Defect, Cerebral Hemorrhage and Cirrhosis - Drug Profile 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 Stem Cell Therapy for Brain Stroke - Drug Profile 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 Brain Hemorrhage - Recent Pipeline Updates 42 Brain Hemorrhage - Dormant Projects 46 Brain Hemorrhage - Discontinued Products 47 Brain Hemorrhage - Product Development Milestones 48 Featured News & Press Releases 48 Apr 03, 2012: MPI Research And Edge Partner To Advance Development Of EG-1964 To Treat Brain Hemorrhage 48 Appendix 49 Methodology 49 Coverage 49 Secondary Research 49 Primary Research 49 Expert Panel Validation 49 Contact Us 49 Disclaimer 50
List of Tables
Number of Products under Development for Brain Hemorrhage, H1 2016 7 Number of Products under Development by Companies, H1 2016 8 Comparative Analysis by Late Stage Development, H1 2016 9 Comparative Analysis by Clinical Stage Development, H1 2016 10 Comparative Analysis by Early Stage Development, H1 2016 11 Products under Development by Companies, H1 2016 12 Brain Hemorrhage - Pipeline by Edge Therapeutics, Inc., H1 2016 13 Brain Hemorrhage - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016 14 Brain Hemorrhage - Pipeline by Fina Biotech, H1 2016 15 Brain Hemorrhage - Pipeline by MediPost Co., Ltd., H1 2016 16 Brain Hemorrhage - Pipeline by Pfizer Inc., H1 2016 17 Brain Hemorrhage - Pipeline by Remedy Pharmaceuticals, Inc., H1 2016 18 Assessment by Monotherapy Products, H1 2016 19 Number of Products by Stage and Target, H1 2016 21 Number of Products by Stage and Mechanism of Action, H1 2016 23 Number of Products by Stage and Route of Administration, H1 2016 25 Number of Products by Stage and Molecule Type, H1 2016 27 Brain Hemorrhage Therapeutics - Recent Pipeline Updates, H1 2016 42 Brain Hemorrhage - Dormant Projects, H1 2016 46 Brain Hemorrhage - Discontinued Products, H1 2016 47
List of Figures
Number of Products under Development for Brain Hemorrhage, H1 2016 7 Number of Products under Development by Companies, H1 2016 8 Comparative Analysis by Early Stage Products, H1 2016 11 Assessment by Monotherapy Products, H1 2016 19 Number of Products by Targets, H1 2016 20 Number of Products by Stage and Targets, H1 2016 20 Number of Products by Mechanism of Actions, H1 2016 22 Number of Products by Stage and Mechanism of Actions, H1 2016 22 Number of Products by Routes of Administration, H1 2016 24 Number of Products by Stage and Routes of Administration, H1 2016 24 Number of Products by Molecule Types, H1 2016 26 Number of Products by Stage and Molecule Types, H1 2016 26
Global CoQ10 market size was 687.2 tons in 2014 and is expected to reach 1,168 tons by 2020, growing at a CAGR of 9.2% from 2014 to 2020, according to a new study by Radiant Insights, Inc. Increasing scope in personal care applications is expected toRead More...
Global gold nanoparticles market size is expected to reach 4.99 billion by 2020, witnessing gains at a CAGR of 24.7%. Positive outlook towards the increasing applications of nanotechnology in medical and dentistry such as drug delivery systems, nanomRead More...
Global lignin market size is expected to exceed USD 6 billion by 2022, growing at 4.9% from 2015 to 2022. Rising demand for animal feed and potential as a feedstock substitute to crude oil are expected to drive lignin market demand over the forecastRead More...
Global animal feed additives market size was estimated at USD 16 billion in 2014. Growing meat consumption as a key protein source, especially in Asia Pacific and Latin America is expected to be a key driver for market demand over the forecast periodRead More...
Global LCP (Liquid Crystal Polymer) industry is forecasted to reach USD 1.23 billion by 2020, as per a new research report by Radiant Insights, Inc. Growing trend towards developing militarized components and connectors are likely to drive the demandRead More...
Get your queries resolved from an industry expert. Request for a free product review before report purchase.
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.